氘标记药物分子的合成进展  

Progress in the Synthesis of Deuterium-labeled Drug Molecules

作　　者：宋瑞捧 刘佳麟 李贝 闫晓宇[3] SONG Ruipeng LIU Jialin LI Bei YAN Xiaoyu(The Third People Hospital of Henan Province, Zhengzhou 450006 School of Life Science and Technology, Shanghai Tech University, Shanghai 201210 Dept. of Chemistry, Renmin University of China, Beijing 100872)

机构地区：[1]河南省直第三人民医院,河南郑州450006 [2]上海科技大学生命科学与技术学院,上海201210 [3]中国人民大学化学系,北京100872

出　　处：《中国医药工业杂志》2017年第6期809-815,共7页Chinese Journal of Pharmaceuticals

摘　　要：氘代药物是将药物分子中的部分氢原子用氘原子取代,在生物学、药学、医学等领域发挥着重要的作用。氘代药物作为一类新型药物已引起业界广泛关注。本文综述了近年来氘标记药物分子的合成方法,主要包括化学合成法和氢氘交换法,并总结这两种方法的优缺点,对其发展前景提出建议。Deuterium-labeled drug molecules, in which partial hydrogen atoms were replaced by deuterium, play an important role in biology, pharmaceutical science, medicine and other fields. In addition, deuterated molecules have attracted much attention as new drugs. In this paper, the synthesis methods of deuterium labeled drug molecules are reviewed, including chemical synthesis and deuterium hydrogen exchange. The advantages and disadvantages of these two methods are summarized and some suggestions for their future development are proposed.

关 键 词：氘代标记 氢氘交换 氘代药物 药物合成 

分 类 号：R97[医药卫生—药品]